Method, array and use thereof
AssigneeImmunovia AB
InventorsCarl Arne Krister Borrebaeck, Christer Lars Bertil Wingren
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from an individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.
Claims63
A method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of:
- a) providing a sample to be tested from the individual;
- b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table A (i), (ii) or (iii);
- wherein the expression in the test sample of the one or more biomarker selected from the group defined in Table A (i), (ii) or (iii) is indicative of the presence of pancreatic cancer.
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of HADH2 and/or TNFRSF3, for example, measuring the expression of HADH2, measuring the expression of TNFRSF3, or measuring the expression of HADH2 and TNFRSF3.
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of each the biomarkers listed in Table A(i).
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more of the biomarkers listed in Table (A)(ii), for example at least 2, 3, 4, 5, 6, 7, 8 or 9 of the biomarkers listed in Table A(ii).
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of all of the biomarkers listed in Table A(ii).
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(iii), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 of the biomarkers listed in Table A(iii).
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(iv), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 of the biomarkers listed in Table A(iv).
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(v), for example at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, or 56 of the biomarkers listed in Table A(v).
The method according to any one of the preceding claims, wherein step (b) comprises or consists of measuring the expression of 1 or more biomarkers from the biomarkers listed in Table A(vi).
The method according to any one of the preceding claims wherein step (b) comprises or consists of measuring the expression in the test sample of all of the biomarkers defined in Table A.
The method according to any one of the preceding claims wherein the pancreatic cancer is selected from the group consisting of adenocarcinoma, adenosquamous carcinoma, signet ring cell carcinoma, hepatoid carcinoma, colloid carcinoma, undifferentiated carcinoma, and undifferentiated carcinomas with osteoclast-like giant cells.
The method according to any one of the preceding claims wherein the pancreatic cancer is an adenocarcinoma.
The method according to any one of the preceding claims wherein step (b), (d) and/or step (f) is performed using a first binding agent capable of binding to the one or more biomarkers.
The method according to any one of the preceding claims wherein the method comprises or consists of an ELISA (Enzyme Linked Immunosorbent Assay).
The method according to any one of the preceding claims wherein step (b), (d) and/or step (f) is performed using an array.
The method according to any one of the preceding claims wherein the method comprises:
- (v) labelling biomarkers present in the sample with biotin;
- (vi) contacting the biotin-labelled proteins with an array comprising a plurality of scFv immobilised at discrete locations on its surface, the scFv having specificity for one or more of the proteins in Table A;
- (vii) contacting the immobilised scFv with a streptavidin conjugate comprising a fluorescent dye;
- and
- (viii) detecting the presence of the dye at discrete locations on the array surface
- wherein the expression of the dye on the array surface is indicative of the expression of a biomarker from Table A in the sample.
The method according to any one of claims wherein, step (b), (d) and/or (f) comprises measuring the expression of a nucleic acid molecule encoding the one or more biomarkers.
The method according to any one of the preceding claims wherein, the sample provided in step (b), (d) and/or (f) is selected from the group consisting of unfractionated blood, plasma, serum, tissue fluid, pancreatic tissue, pancreatic juice, bile and urine.
Use of one or more biomarkers selected from the group defined in Table A as a diagnostic marker for determining the presence of pancreatic cancer in an individual.
A kit according to claim 61 further comprising a second binding agent as defined in any one of claims 35 to 40.
A method or use for determining the presence of pancreatic cancer in an individual substantially as described herein.
An array or kit for determining the presence of pancreatic cancer in an individual substantially as described herein.
Dependencies are inferred from the claim text.